Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry
BioHive-2, an NVIDIA DGX SuperPOD with NVIDIA DGX H100 systems, ranked #35 in the TOP500 list of the most powerful supercomputers in the world across all industries as of May 2024.
Altitude Lab Secures Small Business Administration Growth Fund Accelerator Grant to Launch Horizon, a Commercialization Partnering Program
The grant designates Altitude Lab as a top acceleration program for biotechnology startups
Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also join Recursion’s Board of Directors
Recursion Announces Plans to Open New Office in London
Appoints Michael Bronstein as Scientific Advisor and launches recruiting effort to fill the first 20 open roles across technology and biology, establishing a hub for world-class TechBio talent in the heart of King’s Cross neighborhood
Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection
REC-3964 has been well tolerated in healthy volunteers with no reported serious adverse events. Recursion to explore initiating a Phase 2 proof-of-concept study in patients with recurrent Clostridioides difficile infection in 2024.
Recursion Bridges the Protein and Chemical Space with Massive Protein-Ligand Interaction Predictions Spanning 36 Billion Compounds
Recursion has predicted the protein target(s) for approximately 36 billion chemical compounds in the Enamine REAL Space, reported to be the world’s largest searchable chemical library. These advances were made possible by NVIDIA DGX Cloud supercomputing and the recent acquisition of Cyclica’s MatchMaker technology.
Recursion Celebrates Opening of Its Canadian Headquarters in Toronto with Government Officials and the Biotech Ecosystem
Recursion Celebrates Opening of Its Canadian Headquarters in Toronto with Government Officials and the Biotech Ecosystem
Recursion’s Phase 2 Trial for the Treatment of Cerebral Cavernous Malformation has Fully Enrolled
Recursion’s small molecule is the first therapeutic candidate to be advanced to an industry-sponsored Phase 2 clinical trial for cerebral cavernous malformation (CCM). CCM is a devastating neurovascular disease with approximately 360,000 symptomatic patients in the United States and EU5.
Forbes Recognizes Recursion as a Best Startup Employer
Congratulations to the Recursion team and CEO Chris Gibson on making the Forbes’ list of America’s Best Startup Employers for 2022.
Recursion is Granted Fast Track Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis
Recursion is Granted Fast Track Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2021 Financial Results
Recursion reported business updates and financial results for its fourth quarter and fiscal year ending December 31, 2021.
Recursion loops in Roche, Genentech for multibillion-dollar AI drug discovery deal
The artificial-intelligence-powered drug designer Recursion signed on to a wide-ranging collaboration with Roche and its Genentech division.
